Hold control (command on a Mac) and press the + key as many times as necessary to increase the font size.
Hold control (command on a Mac) and press the - key to reduce the font size. - hide

Tepezza (teprotumumab-trbw) Receives FDA Approval



Posted 1 month ago (0 comments)

BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA's review process.

Comments

  • There are currently no comments

You must log in to comment.

Questions? Problems? Please contact us at [email protected] or 877-643-3123.

GDATF on Facebook

Support the GDATF and become a member today!

© 2020 Graves' Disease & Thyroid Foundation